This marked SBIRs first documented step into DoD acquisition: The Program Manager shall develop an acquisition strategy that plans for the use of technologies developed under the SBIR program, and gives favorable consideration of funding to successful SBIR technologies
During the week of June 15, 2026, FDA issued 25 warning letters to telehealth companies over alleged false or misleading promotional claims about compounded GLP-1 productsclaims the agency views as violating the Federal Food, Drug, and Cosmetic Acts (FDCA) misbranding provisions, including Sections 502(a) and 502(n)
10.1152/jappl.1987.63.1.152 J Appl Physiol
As each person's reaction to glutathione can differ markedly, having an informed discussion with your healthcare provider about the potential benefits and risks is key to tailoring a treatment plan that aligns with your skin whitening aspirations
These findings provide insight into the potential benefits of GLP-1 RAs, but they are preliminary and warrant further investigation